Anterior pituitary adenomas: inherited syndromes, novel genes and molecular pathways

References

• Keil MF, Stratakis CA. Pituitary tumors in childhood: update of diagnosis, treatment and molecular genetics. Expert Rev. Neurother.8(4), 563–574 (2008).
   PubMedGoogle Scholar
• Daly AF, Rixhon M, Adam C, Dempegioti A, Tichomirowa MA, Beckers A. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. J. Clin. Endocrinol. Metab.91(12), 4769–4775 (2006).
   PubMed Web of Science ®Google Scholar
• Ezzat S, Asa SL, Couldwell WT et al. The prevalence of pituitary adenomas: a systematic review. Cancer101(3), 613–619 (2004).
   PubMed Web of Science ®Google Scholar
• Fernandez A, Karavitaki N, Wass JA. Prevalence of pituitary adenomas: a community-based, cross-sectional study in Banbury (Oxfordshire, UK). Clin. Endocrinol. (Oxf.)72(3), 377–382 (2010).
   PubMed Web of Science ®Google Scholar
• Daly AF, Tichomirowa MA, Beckers A. The epidemiology and genetics of pituitary adenomas. Best Pract. Res. Clin. Endocrinol. Metab.23(5), 543–554 (2009).
   PubMed Web of Science ®Google Scholar
• Daly AF, Beckers A. Update on the treatment of pituitary adenomas: familial and genetic considerations. Acta Clin. Belg.63(6), 418–424 (2008).
   PubMed Web of Science ®Google Scholar
• Marx SJ, Simonds WF. Hereditary hormone excess: genes, molecular pathways, and syndromes. Endocr. Rev.26(5), 615–661 (2005).
   PubMedGoogle Scholar
• Scheithauer BW, Laws ER Jr, Kovacs K, Horvath E, Randall RV, Carney JA. Pituitary adenomas of the multiple endocrine neoplasia type I syndrome. Semin. Diagn. Pathol.4(3), 205–211 (1987).
   PubMed Web of Science ®Google Scholar
• Tichomirowa MA, Daly AF, Beckers A. Familial pituitary adenomas. J. Intern. Med.266(1), 5–18 (2009).
   Google Scholar
• Asa SL, Somers K, Ezzat S. The MEN-1 gene is rarely down-regulated in pituitary adenomas. J. Clin. Endocrinol. Metab.83(9), 3210–3212 (1998).
   Google Scholar
• Kaltsas GA, Kola B, Borboli N et al. Sequence analysis of the PRKAR1A gene in sporadic somatotroph and other pituitary tumours. Clin. Endocrinol. (Oxf.)57(4), 443–448 (2002).
   PubMed Web of Science ®Google Scholar
• Lania AG, Mantovani G, Ferrero S et al. Proliferation of transformed somatotroph cells related to low or absent expression of protein kinase a regulatory subunit 1A protein. Cancer Res.64(24), 9193–9198 (2004).
   PubMed Web of Science ®Google Scholar
• Poncin J, Stevenaert A, Beckers A. Somatic MEN1 gene mutation does not contribute significantly to sporadic pituitary tumorigenesis. Eur. J. Endocrinol.140(6), 573–576 (1999).
   Web of Science ®Google Scholar
• Pellegata NS, Quintanilla-Martinez L, Siggelkow H et al. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc. Natl Acad. Sci. USA103(42), 15558–15563 (2006).
   PubMed Web of Science ®Google Scholar
• Vierimaa O, Georgitsi M, Lehtonen R et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science312(5777), 1228–1230 (2006).
   PubMed Web of Science ®Google Scholar
• Daly AF, Vanbellinghen JF, Khoo SK et al. Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. J. Clin. Endocrinol. Metab.92(5), 1891–1896 (2007).
   PubMed Web of Science ®Google Scholar
• Cazabat L, Libe R, Perlemoine K et al. Germline inactivating mutations of the aryl hydrocarbon receptor-interacting protein gene in a large cohort of sporadic acromegaly: mutations are found in a subset of young patients with macroadenomas. Eur. J. Endocrinol.157(1), 1–8 (2007).
   PubMed Web of Science ®Google Scholar
• Georgitsi M, Raitila A, Karhu A et al. Molecular diagnosis of pituitary adenoma predisposition caused by aryl hydrocarbon receptor-interacting protein gene mutations. Proc. Natl Acad. Sci. USA104(10), 4101–4105 (2007).
   PubMed Web of Science ®Google Scholar
• Georgitsi M, Raitila A, Karhu A et al. Germline CDKN1B/p27Kip1 mutation in multiple endocrine neoplasia. J. Clin. Endocrinol. Metab.92(8), 3321–3325 (2007).
   PubMed Web of Science ®Google Scholar
• Agarwal SK, Mateo CM, Marx SJ. Rare germline mutations in cyclin-dependent kinase inhibitor genes in multiple endocrine neoplasia type 1 and related states. J. Clin. Endocrinol. Metab.94(5), 1826–1834 (2009).
   PubMed Web of Science ®Google Scholar
• Verges B, Boureille F, Goudet P et al. Pituitary disease in MEN type 1 (MEN1): data from the France-Belgium MEN1 multicenter study. J. Clin. Endocrinol. Metab.87(2), 457–465 (2002).
   PubMed Web of Science ®Google Scholar
• Matsuzaki LN, Canto-Costa MH, Hauache OM. Cushing’s disease as the first clinical manifestation of multiple endocrine neoplasia type 1 (MEN1) associated with an R460X mutation of the MEN1 gene. Clin. Endocrinol. (Oxf.)60(1), 142–143 (2004).
   Google Scholar
• Rix M, Hertel NT, Nielsen FC et al. Cushing’s disease in childhood as the first manifestation of multiple endocrine neoplasia syndrome type 1. Eur. J. Endocrinol.151(6), 709–715 (2004).
   PubMedGoogle Scholar
• Bilodeau S, Vallette-Kasic S, Gauthier Y et al. Role of Brg1 and HDAC2 in GR trans-repression of the pituitary POMC gene and misexpression in Cushing disease. Genes Dev.20(20), 2871–2886 (2006).
   PubMed Web of Science ®Google Scholar
• Karl M, Von Wichert G, Kempter E et al. Nelson’s syndrome associated with a somatic frame shift mutation in the glucocorticoid receptor gene. J. Clin. Endocrinol. Metab.81(1), 124–129 (1996).
   PubMed Web of Science ®Google Scholar
• Kawashima ST, Usui T, Sano T et al. P53 gene mutation in an atypical corticotroph adenoma with Cushing’s disease. Clin. Endocrinol. (Oxf.)70(4), 656–657 (2009).
   PubMed Web of Science ®Google Scholar
• Hao W, Skarulis MC, Simonds WF et al. Multiple endocrine neoplasia type 1 variant with frequent prolactinoma and rare gastrinoma. J. Clin. Endocrinol. Metab.89(8), 3776–3784 (2004).
   PubMedGoogle Scholar
• Stock JL, Warth MR, Teh BT et al. A kindred with a variant of multiple endocrine neoplasia type 1 demonstrating frequent expression of pituitary tumors but not linked to the multiple endocrine neoplasia type 1 locus at chromosome region 11q13. J. Clin. Endocrinol. Metab.82(2), 486–492 (1997).
   Google Scholar
• Melmed S. Acromegaly pathogenesis and treatment. J. Clin. Invest.119(11), 3189–3202 (2009).
   PubMed Web of Science ®Google Scholar
• Pertuit M, Barlier A, Enjalbert A, Gerard C. Signalling pathway alterations in pituitary adenomas: involvement of Gsα, cAMP and mitogen-activated protein kinases. J. Neuroendocrinol.21(11), 869–877 (2009).
   Google Scholar
• Sands WA, Palmer TM. Regulating gene transcription in response to cyclic AMP elevation. Cell Signal.20(3), 460–466 (2008).
   PubMed Web of Science ®Google Scholar
• Lugnier C. Cyclic nucleotide phosphodiesterase (PDE) superfamily: a new target for the development of specific therapeutic agents. Pharmacol. Ther.109(3), 366–398 (2006).
   PubMed Web of Science ®Google Scholar
• Mantovani G, Ballare E, Giammona E, Beck-Peccoz P, Spada A. The Gsα gene: predominant maternal origin of transcription in human thyroid gland and gonads. J. Clin. Endocrinol. Metab.87(10), 4736–4740 (2002).
   PubMed Web of Science ®Google Scholar
• Dumitrescu CE, Collins MT. McCune-Albright syndrome. Orphanet J. Rare Dis.3, 12 (2008).
   PubMed Web of Science ®Google Scholar
• Volkl TM, Dorr HG. McCune-Albright syndrome: clinical picture and natural history in children and adolescents. J. Pediatr. Endocrinol. Metab.19(Suppl. 2), 551–559 (2006).
   Google Scholar
• Cuttler L, Jackson JA, Saeed uz-Zafar M, Levitsky LL, Mellinger RC, Frohman LA. Hypersecretion of growth hormone and prolactin in McCune-Albright syndrome. J. Clin. Endocrinol. Metab.68(6), 1148–1154 (1989).
   PubMed Web of Science ®Google Scholar
• Kovacs K, Horvath E, Thorner MO, Rogol AD. Mammosomatotroph hyperplasia associated with acromegaly and hyperprolactinemia in a patient with the McCune-Albright syndrome. A histologic, immunocytologic and ultrastructural study of the surgically-removed adenohypophysis. Virchows Arch. A Pathol. Anat. Histopathol.403(1), 77–86 (1984).
   PubMedGoogle Scholar
• Uwaifo GI, Robey PG, Akintoye SO, Collins MT. Clinical picture: fuel on the fire. Lancet357(9273), 2011 (2001).
   Google Scholar
• Galland F, Kamenicky P, Affres H et al. McCune-Albright syndrome and acromegaly: effects of hypothalamopituitary radiotherapy and/or pegvisomant in somatostatin analog-resistant patients. J. Clin. Endocrinol. Metab.91(12), 4957–4961 (2006).
   PubMed Web of Science ®Google Scholar
• Boggild MD, Jenkinson S, Pistorello M et al. Molecular genetic studies of sporadic pituitary tumors. J. Clin. Endocrinol. Metab.78(2), 387–392 (1994).
   PubMedGoogle Scholar
• Clementi E, Malgaretti N, Meldolesi J, Taramelli R. A new constitutively activating mutation of the Gs protein α subunit-Gsp oncogene is found in human pituitary tumours. Oncogene5(7), 1059–1061 (1990).
   PubMedGoogle Scholar
• Landis CA, Masters SB, Spada A, Pace AM, Bourne HR, Vallar L. GTPase inhibiting mutations activate the α chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature340(6236), 692–696 (1989).
   PubMed Web of Science ®Google Scholar
• Bertherat J, Chanson P, Montminy M. The cyclic adenosine 3´,5´-monophosphate-responsive factor CREB is constitutively activated in human somatotroph adenomas. Mol. Endocrinol.9(7), 777–783 (1995).
   PubMedGoogle Scholar
• Picard C, Silvy M, Gerard C et al. Gsα overexpression and loss of Gsα imprinting in human somatotroph adenomas: association with tumor size and response to pharmacologic treatment. Int. J. Cancer121(6), 1245–1252 (2007).
   PubMed Web of Science ®Google Scholar
• Spada A, Arosio M, Bochicchio D et al. Clinical, biochemical, and morphological correlates in patients bearing growth hormone-secreting pituitary tumors with or without constitutively active adenylyl cyclase. J. Clin. Endocrinol. Metab.71(6), 1421–1426 (1990).
   PubMed Web of Science ®Google Scholar
• Ruggeri RM, Santarpia L, Curtò L et al. Non-functioning pituitary adenomas infrequently harbor G-protein gene mutations J. Endocrinol. Invest.31(11), 946–949 (2008).
   Google Scholar
• Persani L, Borgato S, Lania A et al. Relevant cAMP-specific phosphodiesterase isoforms in human pituitary: effect of Gs(α) mutations. J. Clin. Endocrinol. Metab.86(8), 3795–3800 (2001).
   Google Scholar
• Bossis I, Voutetakis A, Bei T, Sandrini F, Griffin KJ, Stratakis CA. Protein kinase A and its role in human neoplasia: the Carney complex paradigm. Endocr. Relat. Cancer11(2), 265–280 (2004).
   PubMed Web of Science ®Google Scholar
• Kirschner LS, Carney JA, Pack SD et al. Mutations of the gene encoding the protein kinase A type I-α regulatory subunit in patients with the Carney complex. Nat. Genet.26(1), 89–92 (2000).
   PubMed Web of Science ®Google Scholar
• Bertherat J, Horvath A, Groussin L et al. Mutations in regulatory subunit type 1A of cyclic adenosine 5’-monophosphate-dependent protein kinase (PRKAR1A): phenotype analysis in 353 patients and 80 different genotypes. J. Clin. Endocrinol. Metab.94(6), 2085–2091 (2009).
   PubMed Web of Science ®Google Scholar
• Pack SD, Kirschner LS, Pak E, Zhuang Z, Carney JA, Stratakis CA. Genetic and histologic studies of somatomammotropic pituitary tumors in patients with the “complex of spotty skin pigmentation, myxomas, endocrine overactivity and schwannomas” (Carney complex). J. Clin. Endocrinol. Metab.85(10), 3860–3865 (2000).
   PubMed Web of Science ®Google Scholar
• Stergiopoulos SG, Abu-Asab MS, Tsokos M, Stratakis CA. Pituitary pathology in Carney complex patients. Pituitary7(2), 73–82 (2004).
   PubMedGoogle Scholar
• Stratakis CA. Cortisol and growth hormone: clinical implications of a complex, dynamic relationship. Pediatr. Endocrinol. Rev.3(Suppl. 2), 333–338 (2006).
   Google Scholar
• Keil MF, Stratakis CA. Advances in the diagnosis, treatment, and molecular genetics of pituitary adenomas in childhood. US Endocrinol.4(2), 81–85 (2009).
   Google Scholar
• Sandrini F, Kirschner LS, Bei T et al. PRKAR1A, one of the Carney complex genes, and its locus (17q22–24) are rarely altered in pituitary tumours outside the Carney complex. J. Med. Genet.39(12), e78 (2002).
   Google Scholar
• Lania A, Filopanti M, Corbetta S et al. Effects of hypothalamic neuropeptides on extracellular signal-regulated kinase (ERK1 and ERK2) cascade in human tumoral pituitary cells. J. Clin. Endocrinol. Metab.88(4), 1692–1696 (2003).
   PubMed Web of Science ®Google Scholar
• Mantovani G, Bondioni S, Ferrero S et al. Effect of cyclic adenosine 3´,5´-monophosphate/protein kinase a pathway on markers of cell proliferation in nonfunctioning pituitary adenomas. J. Clin. Endocrinol. Metab.90(12), 6721–6724 (2005).
   PubMed Web of Science ®Google Scholar
• Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature410(6824), 37–40 (2001).
   PubMed Web of Science ®Google Scholar
• Raman M, Chen W, Cobb MH. Differential regulation and properties of MAPKs. Oncogene26(22), 3100–3112 (2007).
   PubMed Web of Science ®Google Scholar
• McKay MM, Morrison DK. Integrating signals from RTKs to ERK/MAPK. Oncogene26(22), 3113–3121 (2007).
   PubMed Web of Science ®Google Scholar
• Weston CR, Lambright DG, Davis RJ. Signal transduction. MAP kinase signaling specificity. Science296(5577), 2345–2347 (2002).
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Ebisuya M, Ashida F, Okamoto K, Yonehara S, Nishida E. Continuous ERK activation downregulates antiproliferative genes throughout G1 phase to allow cell-cycle progression. Curr. Biol.16(12), 1171–1182 (2006).
   PubMed Web of Science ®Google Scholar
• Stork PJ, Schmitt JM. Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation. Trends Cell Biol.12(6), 258–266 (2002).
   PubMed Web of Science ®Google Scholar
• Leevers SJ, Vanhaesebroeck B, Waterfield MD. Signalling through phosphoinositide 3-kinases: the lipids take centre stage. Curr. Opin. Cell Biol.11(2), 219–225 (1999).
   PubMed Web of Science ®Google Scholar
• Carracedo A, Pandolfi PP. The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene27(41), 5527–5541 (2008).
   PubMed Web of Science ®Google Scholar
• Zebisch A, Troppmair J. Back to the roots: the remarkable RAF oncogene story. Cell. Mol. Life Sci.63(11), 1314–1330 (2006).
   PubMed Web of Science ®Google Scholar
• Dhillon AS, Hagan S, Rath O, Kolch W. MAP kinase signalling pathways in cancer. Oncogene26(22), 3279–3290 (2007).
   PubMed Web of Science ®Google Scholar
• Fernandez M, Sanchez-Franco F, Palacios N, Sanchez I, Fernandez C, Cacicedo L. IGF-I inhibits apoptosis through the activation of the phosphatidylinositol 3-kinase/Akt pathway in pituitary cells. J. Mol. Endocrinol.33(1), 155–163 (2004).
   PubMed Web of Science ®Google Scholar
• Fernandez M, Sanchez-Franco F, Palacios N, Sanchez I, Villuendas G, Cacicedo L. Involvement of vasoactive intestinal peptide on insulin-like growth factor I-induced proliferation of rat pituitary lactotropes in primary culture: evidence for an autocrine and/or paracrine regulatory system. Neuroendocrinology77(5), 341–352 (2003).
   PubMed Web of Science ®Google Scholar
• Romano D, Magalon K, Pertuit M et al. Conditional overexpression of the wild-type Gs α as the GSP oncogene initiates chronic extracellularly regulated kinase 1/2 activation and hormone hypersecretion in pituitary cell lines. Endocrinology148(6), 2973–2983 (2007).
   PubMed Web of Science ®Google Scholar
• Lin Y, Jiang X, Shen Y et al. Frequent mutations and amplifications of the PIK3CA gene in pituitary tumors. Endocr. Relat. Cancer16(1), 301–310 (2009).
   PubMed Web of Science ®Google Scholar
• Ewing I, Pedder-Smith S, Franchi G et al. A mutation and expression analysis of the oncogene BRAF in pituitary adenomas. Clin. Endocrinol. (Oxf.)66(3), 348–352 (2007).
   PubMed Web of Science ®Google Scholar
• Musat M, Korbonits M, Kola B et al. Enhanced protein kinase B/Akt signalling in pituitary tumours. Endocr. Relat. Cancer12(2), 423–433 (2005).
   PubMed Web of Science ®Google Scholar
• Marx S, Spiegel AM, Skarulis MC, Doppman JL, Collins FS, Liotta LA. Multiple endocrine neoplasia type 1: clinical and genetic topics. Ann. Intern. Med.129(6), 484–494 (1998).
   PubMed Web of Science ®Google Scholar
• Agarwal SK, Kennedy PA, Scacheri PC et al. Menin molecular interactions: insights into normal functions and tumorigenesis. Horm. Metab. Res.37(6), 369–374 (2005).
   PubMed Web of Science ®Google Scholar
• Milne TA, Hughes CM, Lloyd R et al. Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. Proc. Natl Acad. Sci. USA102(3), 749–754 (2005).
   PubMed Web of Science ®Google Scholar
• Lemos MC, Thakker RV. Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. Hum. Mutat.29(1), 22–32 (2008).
   PubMed Web of Science ®Google Scholar
• Beckers A, Betea D, Valdes Socin H, Stevenaert A. The treatment of sporadic versus MEN1-related pituitary adenomas. J. Intern. Med.253(6), 599–605 (2003).
   PubMed Web of Science ®Google Scholar
• Theodoropoulou M, Cavallari I, Barzon L et al. Differential expression of menin in sporadic pituitary adenomas. Endocr. Relat. Cancer11(2), 333–344 (2004).
   PubMed Web of Science ®Google Scholar
• Ozawa A, Agarwal SK, Mateo CM et al. The parathyroid/pituitary variant of multiple endocrine neoplasia type 1 usually has causes other than p27Kip1 mutations. J. Clin. Endocrinol. Metab.92(5), 1948–1951 (2007).
   Google Scholar
• Fritz A, Walch A, Piotrowska K et al. Recessive transmission of a multiple endocrine neoplasia syndrome in the rat. Cancer Res.62(11), 3048–3051 (2002).
   Web of Science ®Google Scholar
• Vandeva S, Tichomirowa MA, Zacharieva S, Daly AF, Beckers A. Genetic factors in the development of pituitary adenomas. Endocr. Dev.17, 121–133 (2010).
   Google Scholar
• Jin L, Qian X, Kulig E et al. Transforming growth factor-β, transforming growth factor-β receptor II, and p27Kip1 expression in nontumorous and neoplastic human pituitaries. Am. J. Pathol.151(2), 509–519 (1997).
   PubMed Web of Science ®Google Scholar
• Korbonits M, Chahal HS, Kaltsas G et al. Expression of phosphorylated p27(Kip1) protein and Jun activation domain-binding protein 1 in human pituitary tumors. J. Clin. Endocrinol. Metab.87(6), 2635–2643 (2002).
   PubMed Web of Science ®Google Scholar
• Verloes A, Stevenaert A, Teh BT, Petrossians P, Beckers A. Familial acromegaly: case report and review of the literature. Pituitary1(3–4), 273–277 (1999).
   Google Scholar
• Leontiou CA, Gueorguiev M, van der Spuy J et al. The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. J. Clin. Endocrinol. Metab.93(6), 2390–2401 (2008).
   PubMed Web of Science ®Google Scholar
• Daly AF, Tichomirowa MA, Beckers A. Genetic, molecular and clinical features of familial isolated pituitary adenomas. Horm. Res.71(Suppl. 2), 116–122 (2009).
   Google Scholar
• Daly AF, Jaffrain-Rea ML, Ciccarelli A et al. Clinical characterization of familial isolated pituitary adenomas. J. Clin. Endocrinol. Metab.91(9), 3316–3323 (2006).
   PubMed Web of Science ®Google Scholar
• Barlier A, Vanbellinghen JF, Daly AF et al. Mutations in the aryl hydrocarbon receptor interacting protein gene are not highly prevalent among subjects with sporadic pituitary adenomas. J. Clin. Endocrinol. Metab.92(5), 1952–1955 (2007).
   PubMed Web of Science ®Google Scholar
• Pei L, Melmed S. Isolation and characterization of a pituitary tumor-transforming gene (PTTG). Mol. Endocrinol.11(4), 433–441 (1997).
   PubMed Web of Science ®Google Scholar
• Salehi F, Kovacs K, Scheithauer BW, Lloyd RV, Cusimano M. Pituitary tumor-transforming gene in endocrine and other neoplasms: a review and update. Endocr. Relat. Cancer15(3), 721–743 (2008).
   PubMed Web of Science ®Google Scholar
• Abbud RA, Takumi I, Barker EM et al. Early multipotential pituitary focal hyperplasia in the α-subunit of glycoprotein hormone-driven pituitary tumor-transforming gene transgenic mice. Mol. Endocrinol.19(5), 1383–1391 (2005).
   Google Scholar
• Folkman J, Klagsbrun M. Angiogenic factors. Science235(4787), 442–447 (1987).
   PubMed Web of Science ®Google Scholar
• Chesnokova V, Zonis S, Kovacs K et al. p21(Kip1) restrains pituitary tumor growth. Proc. Natl Acad. Sci. USA105(45), 17498–17503 (2008).
   PubMed Web of Science ®Google Scholar
• Barboza JA, Liu G, Ju Z, El-Naggar AK, Lozano G. p21 delays tumor onset by preservation of chromosomal stability. Proc. Natl Acad. Sci. USA103(52), 19842–19847 (2006).
   PubMed Web of Science ®Google Scholar
• Shen KC, Heng H, Wang Y et al. ATM and p21 cooperate to suppress aneuploidy and subsequent tumor development. Cancer Res.65(19), 8747–8753 (2005).
   Google Scholar
• Mooi WJ, Peeper DS. Oncogene-induced cell senescence – halting on the road to cancer. N. Engl. J. Med.355(10), 1037–1046 (2006).
   PubMed Web of Science ®Google Scholar
• Chesnokova V, Zonis S, Rubinek T et al. Senescence mediates pituitary hypoplasia and restrains pituitary tumor growth. Cancer Res.67(21), 10564–10572 (2007).
   PubMedGoogle Scholar
• Uccella S, Tibiletti MG, Bernasconi B, Finzi G, Oldrini R, Capella C. Aneuploidy, centrosome alteration and securin overexpression as features of pituitary somatotroph and lactotroph adenomas. Anal. Quant. Cytol. Histol.27(5), 241–252 (2005).
   Google Scholar
• Bazina M, Vukojevic K, Roje D, Saraga-Babic M. Influence of growth and transcriptional factors, and signaling molecules on early human pituitary development. J. Mol. Histol.40(4), 277–286 (2009).
   Google Scholar
• McAndrew J, Paterson AJ, Asa SL, McCarthy KJ, Kudlow JE. Targeting of transforming growth factor-α expression to pituitary lactotrophs in transgenic mice results in selective lactotroph proliferation and adenomas. Endocrinology136(10), 4479–4488 (1995).
   PubMed Web of Science ®Google Scholar
• LeRiche VK, Asa SL, Ezzat S. Epidermal growth factor and its receptor (EGF-R) in human pituitary adenomas: EGF-R correlates with tumor aggressiveness. J. Clin. Endocrinol. Metab.81(2), 656–662 (1996).
   PubMed Web of Science ®Google Scholar
• Saeger W. Expression of growth factors in normal and neoplastic pituitary tissues. Endocr. Pathol.11(4), 295–300 (2000).
   Google Scholar
• Ezzat S, Zheng L, Zhu XF, Wu GE, Asa SL. Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis. J. Clin. Invest.109(1), 69–78 (2002).
   PubMed Web of Science ®Google Scholar
• Morita K, Takano K, Yasufuku-Takano J et al. Expression of pituitary tumour-derived, N-terminally truncated isoform of fibroblast growth factor receptor 4 (ptd-FGFR4) correlates with tumour invasiveness but not with G-protein α subunit (GSP) mutation in human GH-secreting pituitary adenomas. Clin. Endocrinol. (Oxf.)68(3), 435–441 (2008).
   Google Scholar
• Massague J. How cells read TGF-β signals. Nat. Rev. Mol. Cell Biol.1(3), 169–178 (2000).
   PubMed Web of Science ®Google Scholar
• Kawabata M, Imamura T, Miyazono K. Signal transduction by bone morphogenetic proteins. Cytokine Growth Factor Rev.9(1), 49–61 (1998).
   PubMed Web of Science ®Google Scholar
• Gilboa L, Nohe A, Geissendorfer T, Sebald W, Henis YI, Knaus P. Bone morphogenetic protein receptor complexes on the surface of live cells: a new oligomerization mode for serine/threonine kinase receptors. Mol. Biol. Cell11(3), 1023–1035 (2000).
   PubMedGoogle Scholar
• Heldin CH, Miyazono K, ten Dijke P. TGF-β signalling from cell membrane to nucleus through SMAD proteins. Nature390(6659), 465–471 (1997).
   PubMed Web of Science ®Google Scholar
• Haedo MR, Gerez J, Fuertes M et al. Regulation of pituitary function by cytokines. Horm. Res.72(5), 266–274 (2009).
   Google Scholar
• Giacomini D, Paez-Pereda M, Theodoropoulou M et al. Bone morphogenetic protein-4 control of pituitary pathophysiology. Front. Horm. Res.35, 22–31 (2006).
   Google Scholar
• Paez-Pereda M, Giacomini D, Refojo D et al. Involvement of bone morphogenetic protein 4 (BMP-4) in pituitary prolactinoma pathogenesis through a Smad/estrogen receptor crosstalk. Proc. Natl Acad. Sci. USA100(3), 1034–1039 (2003).
   PubMed Web of Science ®Google Scholar
• Giacomini D, Haedo M, Gerez J et al. Differential gene expression in models of pituitary prolactin-producing tumoral cells. Horm. Res.71(Suppl. 2), 88–94 (2009).
   Google Scholar
• Kurie JM. The biologic basis for the use of retinoids in cancer prevention and treatment. Curr. Opin Oncol.11(6), 497–502 (1999).
   PubMedGoogle Scholar
• Paez-Pereda M, Kovalovsky D, Hopfner U et al. Retinoic acid prevents experimental Cushing syndrome. J. Clin. Invest.108(8), 1123–1131 (2001).
   PubMed Web of Science ®Google Scholar
• Weinberg RA. The retinoblastoma protein and cell cycle control. Cell81(3), 323–330 (1995).
   PubMed Web of Science ®Google Scholar
• Jacks T, Fazeli A, Schmitt EM, Bronson RT, Goodell MA, Weinberg RA. Effects of an Rb mutation in the mouse. Nature359(6393), 295–300 (1992).
   PubMed Web of Science ®Google Scholar
• Honda S, Tanaka-Kosugi C, Yamada S et al. Human pituitary adenomas infrequently contain inactivation of retinoblastoma 1 gene and activation of cyclin dependent kinase 4 gene. Endocr. J.50(3), 309–318 (2003).
   Google Scholar
• Simpson DJ, Hibberts NA, McNicol AM, Clayton RN, Farrell WE. Loss of pRb expression in pituitary adenomas is associated with methylation of the Rb1 CpG island. Cancer Res.60(5), 1211–1216 (2000).
   PubMed Web of Science ®Google Scholar
• Yoshino A, Katayama Y, Ogino A et al. Promoter hypermethylation profile of cell cycle regulator genes in pituitary adenomas. J. Neurooncol.83(2), 153–162 (2007).
   PubMed Web of Science ®Google Scholar
• Fedele M, Fusco A. Role of the high mobility group A (HMGA) proteins in the regulation of pituitary cell cycle. J. Mol. Endocrinol.44(6), 309–118 (2010).
   PubMed Web of Science ®Google Scholar
• Fusco A, Fedele M. Roles of HMGA proteins in cancer. Nat. Rev. Cancer7(12), 899–910 (2007).
   PubMed Web of Science ®Google Scholar
• Ashar HR, Fejzo MS, Tkachenko A et al. Disruption of the architectural factor HMGI-C: DNA-binding AT hook motifs fused in lipomas to distinct transcriptional regulatory domains. Cell82(1), 57–65 (1995).
   PubMed Web of Science ®Google Scholar
• Schoenmakers EF, Wanschura S, Mols R, Bullerdiek J, Van den Berghe H, Van de Ven WJ. Recurrent rearrangements in the high mobility group protein gene, HMGI-C, in benign mesenchymal tumours. Nat. Genet.10(4), 436–444 (1995).
   PubMed Web of Science ®Google Scholar
• Fedele M, Battista S, Kenyon L et al. Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas. Oncogene21(20), 3190–3198 (2002).
   PubMed Web of Science ®Google Scholar
• Fedele M, Visone R, De Martino I et al. HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity. Cancer Cell9(6), 459–471 (2006).
   PubMed Web of Science ®Google Scholar
• Pagotto U, Arzberger T, Theodoropoulou M et al. The expression of the antiproliferative gene ZAC is lost or highly reduced in nonfunctioning pituitary adenomas. Cancer Res.60(24), 6794–6799 (2000).
   PubMed Web of Science ®Google Scholar
• Zhao J, Dahle D, Zhou Y, Zhang X, Klibanski A. Hypermethylation of the promoter region is associated with the loss of MEG3 gene expression in human pituitary tumors. J. Clin. Endocrinol. Metab.90(4), 2179–2186 (2005).
   PubMed Web of Science ®Google Scholar
• Zhang X, Rice K, Wang Y et al. Maternally expressed gene 3 (MEG3) noncoding ribonucleic acid: isoform structure, expression, and functions. Endocrinology151(3), 939–947 (2010).
   PubMed Web of Science ®Google Scholar
• Gejman R, Batista DL, Zhong Y et al. Selective loss of MEG3 expression and intergenic differentially methylated region hypermethylation in the MEG3/DLK1 locus in human clinically nonfunctioning pituitary adenomas. J. Clin. Endocrinol. Metab.93(10), 4119–4125 (2008).
   PubMedGoogle Scholar
• Zhao J, Zhang X, Zhou Y, Ansell PJ, Klibanski A. Cyclic AMP stimulates MEG3 gene expression in cells through a cAMP-response element (CRE) in the MEG3 proximal promoter region. Int. J. Biochem. Cell Biol.38(10), 1808–1820 (2006).
   Google Scholar
• Ezzat S, Asa SL. The emerging role of the Ikaros stem cell factor in the neuroendocrine system. J. Mol. Endocrinol.41(2), 45–51 (2008).
   PubMedGoogle Scholar
• Ezzat S, Yu S, Asa SL. Ikaros isoforms in human pituitary tumors: distinct localization, histone acetylation, and activation of the 5´ fibroblast growth factor receptor-4 promoter. Am. J. Pathol.163(3), 1177–1184 (2003).
   PubMed Web of Science ®Google Scholar
• Dudley KJ, Revill K, Clayton RN, Farrell WE. Pituitary tumours: all silent on the epigenetics front. J. Mol. Endocrinol.42(6), 461–468 (2009).
   PubMed Web of Science ®Google Scholar
• Stratakis CA, Tichomirowa MA, Boikos S et al. The role of germline AIP, MEN1, PRKAR1A,CDKN1B and CDKN2C mutations causing pituitary adenomas in large cohort of children, adolescents and patients with genetic syndromes. Clin. Genet. (2010) (In press).
   Google Scholar
• Georgitsi M, De Menis E, Cannavò S et al. Aryl hydrocarbon receptor interacting protein (AIP) gene mutation analysis in children and adolescents with sporadic pituitary adenomas. Clin. Endocrinol. (Oxf.)69(4), 621–627 (2008).
   PubMed Web of Science ®Google Scholar